2011

How much money the pharmaceutical industry spends on Internet marketing, direct-to-consumer advertising, and physician detailing are always topics of interest and 2010 was no exception. 2010 was, however, a turning point in bringing more attention to payments made to physicians for speaking, consulting, and research.

Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.

Welcome to Volume 10, Issue No. 1 (Jan 12, 2011) of Pharma Marketing News. This issue of Pharma Marketing News is devoted to the Pharma Marketing Yearbook (PMY), which is a commemorative record of pharmaceutical marketing issues and highlights of the past year.

This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.

A conversation with Monique Levy, VP Research at Manhattan Research, about the changing pharma eDetailing landscape. Ms. Levy discusses how the online pharma promotion landscape has changed, and which types of programs garner the largest audience as well as how the rep relationship is evolving and the role of new technologies such as tablets.

Every year without fail there are revelations about pharmaceutical companies behaving badly -- companies that have been charged with crimes such as making kickbacks to physicians, engaging in Medicare and Medicaid fraud, promoting products off label to physicians or companies that are called to testify before Congress about sub par manufacturing practices. 2010 seems to be unique in the number of companies behaving badly.

Were FDA's infamous 14 warning letters to pharma a ploy to force Google into a $500M DOJ settlement regarding illegal online pharmacy ads? In addition, could FDA have been holding back issuing pharma social media guidelines -- which would include guidelines for displayig compliant information in space-limited applications such as Twitter AND Google Adwords -- until Google settled its case with the DOJ?

Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.

Why do pharma companies bother developing drugs for for a disorder affecting fewer than 200,000 people? Willie Sutton's ghost may have the answer.

Welcome to Volume 10, Issue #19 (21 DECEMBER 2011) of Pharma Marketing News.